Your Brief Filament Health announces the completion of its first GMP batch of natural psilocybin extract, which it expects to administer via clinical trials conducted in collaboration with UCSF’s Translational Psychedelic Research Program (TrPR). Filament expects this clinical trial to be the first FDA-approved study conducted with natural psilocybin. Full press release… Vancouver…


Previous articlePTSF63 – The Media and Legalization, Joints for Jabs, and 40,000 Ecstasy Pills
Next articlePsychedelic Bulletin: MindMed CEO Steps Down; Atai Targets $2.3bn Valuation